Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Redhill BiopharmaSTU:2RH 18 10-Year RORE % is -18.79 as of Dec. 2025. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 670 Drug Manufacturers companies, Redhill Biopharma ranks worse than 82.69% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Redhill Biopharma's 10-Year RORE % for the quarter that ended in Dec. 2025 was -18.79%.
The industry rank for Redhill Biopharma's 10-Year RORE % or its related term are showing as below:
STU:2RH's 10-Year RORE % is ranked worse than 82.69% of 670
companies
in the Drug Manufacturers industry
Industry Median: 6.47
vs STU:2RH: -18.79
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Redhill Biopharma 10-Year RORE % Related Terms
Redhill Biopharma 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Redhill Biopharma's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2RH vs SBFM, PRFX, CTTH: 10-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redhill Biopharma 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Redhill Biopharma's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.
Redhill Biopharma (STU:2RH) has a 10-Year RORE % of -18.79 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Redhill Biopharma and its competitors. According to the industry distribution chart, Redhill Biopharma ranks #554 out of 670 companies in the Drug Manufacturers industry, placing it in the top 82.7%.
Is Redhill Biopharma's 10-Year RORE % too high?
Redhill Biopharma's current 10-Year RORE % is -18.79. Based on the distribution chart, Redhill Biopharma ranks #554 out of 670 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's 10-Year RORE % compare to SBFM and PRFX?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #554 out of 670 companies for 10-Year RORE %. This places Redhill Biopharma in the lower half of its industry. The industry median 10-Year RORE % is 6.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.47, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current 10-Year RORE % is -18.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current 10-Year RORE % of -18.79. The current 10-Year RORE % is -18.79. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current 10-Year RORE % is -18.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score
Get the complete analysis for STU:2RH
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RH has been successfully added to your 
